Navegando por Autor "BENTES, Alessandra Quinto"

Agora exibindo 1 - 3 de 3

Acesso aberto (Open Access)
Diagnóstico de imunofenótipos de síndromes linfoproliferativas crônicas por citometria de fluxo na Fundação HEMOPA
(2011-12) BRITO JUNIOR, Lacy Cardoso de; FEIO, Danielle Cristinne Azevedo; BARBOSA, Suane Reis; BENTES, Alessandra Quinto; FRANCÊS, Larissa Tatiane Martins
INTRODUCTION: Lymphoproliferative syndromes comprise a heterogeneous group of malignant neoplasias with different clinical behaviors, pathological factors and epidemiological characteristics, whose diagnosis may be based on lymphoid cell morphology observed in peripheral blood. OBJECTIVE: To test the diagnostic feasibility of immunophenotyping by flow cytometry for lymphoproliferative syndromes through the definition of minimal antibody panel. MATERIAL AND METHODS: During the period of July 2008 to July 2010, 47 patients from HEMOPA blood center participated in this study for differential diagnosis of lymphoproliferative syndromes subtypes by flow cytometry. RESULTS: The mean age was 68 years old. There was no statistical difference between genders, and the most frequent subtype of lymphoproliferative syndromes was chronic lymphoid leukemia/small B-cell lymphocytic lymphoma. CONCLUSION: Based on the antibody panel recommended in this investigation, the immunophenotyping method by flow cytometry associated with morphological characterization of peripheral blood samples is a reliable, rapid, feasible, and non-invasive procedure for the diagnosis of chronic lymphoproliferative syndromes.
Desconhecido
Frequency of acute myeloid leukemia in children attended in Belém, Pará from August 2005 to May 2009
(2015-04) BRITO JUNIOR, Lacy Cardoso de; LEVY, Ian Eliezer; FRANCÊS, Larissa Tatiane Martins; WANDERLEY, Alayde Vieira; CARNEIRO, Rita de Cassia Matos; BENTES, Alessandra Quinto
Introduction: Acute myeloid leukemia (AML) has variable incidence in different regions of Brazil. Objective: To determine the frequency of AML subtypes in children aged 0-17 years attended at Belém, Pará, from August 2005 to May 2009. Patients and methods: A retrospective study was performed with 278 patients diagnosed with acute or chronic leukemia based on clinical and morphological criteria (French-American-British [FAB]/World Health Organization classification [WHO]) and immunophenotyping profile by flow cytometry, to determine the frequency of the subtypes in AML. Results: We found 70 (25.18%) cases of AML, 37 of these (52.9%) were children aged 0-17 years (median age of 7 years and 8 months). There was no statistical difference in relation to gender. We observed a higher frequency of AML subtype M2 (18/37 - 48.6%) and M0/M1 (10/37 - 27%), especially in the first decade of life (16/28 [57.1%] AML M2 and 9/28 [32.1%] AML M0/M1). Conclusion: In the pediatric population, the types of AML M2, M0/M1 and M3 were respectively the most frequent.
Desconhecido
Influence of late treatment on how chronic myeloid leukemia responds to imatinib
(2009) SCERNI, Ana Carolina Costa; ALVARES, Leonardo Azevedo; BELTRÃO, Ana Cristina; BENTES, Iê Regina; AZEVEDO, Tereza Cristina; BENTES, Alessandra Quinto; LEMOS, José Alexandre Rodrigues de
INTRODUCTION: In Brazil, patients with chronic myeloid leukemia (CML) in the chronic phase were not given first-line imatinib treatment until 2008. Therefore, there was a long period of time between diagnosis and the initiation of imatinib therapy for many patients. This study aims to compare the major molecular remission (MMR) rates of early versus late imatinib therapy in chronic phase CML patients. METHODS: Between May 2002 and November 2007, 44 patients with chronic phase CML were treated with second-line imatinib therapy at the Hematology Unit of the Ophir Loyola Hospital (Belém, Pará, Brazil). BCR-ABL transcript levels were measured at approximately six-month intervals using quantitative polymerase chain reaction. RESULTS: The early treatment group presented a 60% probability of achieving MMR, while the probability for those patients who received late treatment was 40%. The probability of either not achieving MMR within one year of the initiation of imatinib therapy or losing MMR was higher in patients who received late treatment (79%), compared with patients who received early treatment (21%, odds ratio=5.75, P=0.012). The probability of maintaining MMR at 30 months of treatment was 80% in the early treatment group and 44% in the late treatment group (P=0.0005). CONCLUSIONS: For CML patients in the chronic phase who were treated with second-line imatinib therapy, the probability of achieving and maintaining MMR was higher in patients who received early treatment compared with those patients for whom the time interval between diagnosis and initiation of imatinib therapy was longer than one year.